Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): <scp>D</scp> ata from randomized controlled trialsMatteo Monami, Edoardo Mannucci, Alessia Scatena et al.|Diabetes Obesity and Metabolism|2017Cited by 226
The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanismFrancesco Andreozzi, Franco Folli|Journal of Translational Medicine|2016Cited by 101
Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistanceFrancesco Andreozzi, Giorgio Sesti|Diabetologia|2011Cited by 80